trending Market Intelligence /marketintelligence/en/news-insights/trending/Kechu9ZGaZKlZxiFypAaIg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

ZIOPHARM sees positive updated results for phase 1 trial of glioblastoma drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ZIOPHARM sees positive updated results for phase 1 trial of glioblastoma drug

ZIOPHARM Oncology Inc. reported positive updated results from its phase 1 study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or progressive glioblastoma.

The results were from 25 patients with recurrent or progressive grade III or IV glioma enrolled in three veledimex dosing cohorts of 20 milligrams, 30 mg and 40 mg.

As of May 24, median overall survival of all patients receiving intratumoral Ad-RTS-hIL-12 with 20 mg of orally administered veledimex was maintained at 12.5 months, continuing to compare favorably to historical controls. Mean follow-up time was 9.2 months. The majority of patients in the 20 mg cohort had two or more recurrences prior to joining the study.

The company said survival appears correlated with IL-12-mediated cellular immune activation, and that steroid use in the first 15 days after injection of the virus appears to have a deleterious effect on patient survival.